Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quinacainol (RP 54272)是一种新的抗心律失常化合物,在大鼠中具有I类抗心律失常作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,000 | 现货 | ||
5 mg | ¥ 2,500 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,890 | 现货 | ||
50 mg | ¥ 8,290 | 现货 | ||
100 mg | ¥ 11,200 | 现货 |
产品描述 | Quinacainol (RP 54272) is a new antiarrhythmic compound with class I antiarrhythmic effects in rats. |
体外活性 | Quinacainol blocked sodium currents in a concentration-dependent manner and with a potency similar to that of quinidine (mean (+/-SEM) EC50 50+/-12 vs 95+/-25 micromol/L for quinidine and quinacainol, respectively). Quinacainol, a quinidine analog, blocks sodium currents in cardiac myocytes with little effect on I (to) or iKsus potassium currents, which suggests that quinacainol may be exerting class 1c anti-arrhythmic actions.[1] |
体内活性 | Evaluation of antiarrhythmic effects using Quinacainol in conscious rats with LAD coronary artery occlusion. Antiarrhythmic actions occurred with 2.0 and 4.0 mg/kg, whereas 8.0 mg/kg was pro-arrhythmic. At doses of 0.5 mg/kg and above, quinacainol increased threshold currents for capture and for ventricular fibrillation. Doses of 2.0 mg/kg and above increased ventricular refractoriness. From 1.0 to 8.0 mg/kg, quinacainol reduced dV/dtmax of phase 0 of epicardial action potentials but only 8.0 mg/kg increased action potential duration. The Q-T interval was also increased with the highest dose. Quinacainol dose-relatedly increased P-R interval whereas QRS did not change. Thus the Class I electrophysiological properties of quinacainol over the dose range tested did not fit accurately into a single subclass of the various subclasses of Class I. However, the Class Ic actions seen with 2.0 and 4.0 mg/kg were associated with antiarrhythmic actions.[2] |
别名 | PK-10139, RP-54272, RP 54272, PK 10139, PK10139 |
分子量 | 326.48 |
分子式 | C21H30N2O |
CAS No. | 86073-85-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (153.15 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.063 mL | 15.3149 mL | 30.6297 mL | 76.5744 mL |
5 mM | 0.6126 mL | 3.063 mL | 6.1259 mL | 15.3149 mL | |
10 mM | 0.3063 mL | 1.5315 mL | 3.063 mL | 7.6574 mL | |
20 mM | 0.1531 mL | 0.7657 mL | 1.5315 mL | 3.8287 mL | |
50 mM | 0.0613 mL | 0.3063 mL | 0.6126 mL | 1.5315 mL | |
100 mM | 0.0306 mL | 0.1531 mL | 0.3063 mL | 0.7657 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Quinacainol 86073-85-0 Others PK-10139 RP-54272 RP 54272 PK 10139 RP54272 PK10139 Inhibitor inhibitor inhibit